Chugai Pharmaceutical has patented target tissue-specific antigen-binding molecules that vary in activity based on small molecule concentration. The invention includes libraries of diverse antigen-binding domains for treating diseases in a tissue-specific manner. GlobalData’s report on Chugai Pharmaceutical gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Chugai Pharmaceutical Co Ltd - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Chugai Pharmaceutical, was a key innovation area identified from patents. Chugai Pharmaceutical's grant share as of February 2024 was 31%. Grant share is based on the ratio of number of grants to total number of patents.

Target tissue-specific antigen-binding molecules library

Source: United States Patent and Trademark Office (USPTO). Credit: Chugai Pharmaceutical Co Ltd

A recently granted patent (Publication Number: US11912989B2) discloses a library comprising a variety of antigen-binding domains or molecules with different amino acid sequences, encoding nucleic acids, and small molecule compounds. The library includes a first antigen-binding domain whose affinity for a specific antigen is influenced by the concentration of a small molecule compound, which is not the antigen itself. The small molecule compound can be non-naturally occurring or naturally found in cancer or inflammatory tissues, such as nucleosides, amino acids, lipids, primary metabolites, or specific compounds like kynurenine and adenosine.

Furthermore, the library consists of antigen-binding molecules with amino acid substitutions at specific positions, not involved in binding to the small molecule compound, or showing diversity in amino acid occurrence frequency. The library may also include fusion polypeptides combining antigen-binding domains with virus coat proteins. The patent also describes a method for screening the library to identify antigen-binding molecules that exhibit varying binding affinities to an antigen based on the concentration of a small molecule compound present. This method involves contacting the antigen-binding domains with the antigen in the presence of different concentrations of the small molecule compound to determine their binding specificity. The antigen-binding domains can be in the form of Fab fragments, single-chain Fv (scFv), or fused with viral coat proteins.

To know more about GlobalData’s detailed insights on Chugai Pharmaceutical, buy the report here.

This content was updated on 25 January 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies